Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Sequential CD19- and CD22-Directed CAR T-Cell Therapy Improves Long-Term Remission in Relapsed/Refractory B-ALL

Virginia Powers, PhD
Published: Wednesday, Mar 27, 2019

blood cellsSequential administration of CAR T-cell therapy targeting both the CD19 and CD22 antigens demonstrated high complete remission (CR) rates and improved long-term survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) following allogeneic hematopoietic stem cell transplant (HSCT), according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication